© 2022 MJH Life Sciences and CGTLive™. All rights reserved.
© 2022 MJH Life Sciences™ and CGTLive™. All rights reserved.
June 23, 2022
The phase 1/2 OVATION 2 study is expected to complete enrollment by the third quarter of this year.
June 21, 2022
All children in the phase 3 SPR1NT study achieved the primary end point of independent sitting.
The treated patient achieved an overall partial response of 72% in tumor regression.
June 18, 2022
A multisite phase 1 clinical trial for NT-I7 is underway in patients with relapsed/refractory large B-cell lymphoma.
June 16, 2022
CTX130 is also being investigated for the treatment of r/r renal cell carcinoma in a phase 1 clinical trial called COBALT-RCC (NCT04438083).
June 15, 2022
Among treated patients, 42% achieved 5-year event free survival.